Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1537 to 1543 of 1543 entries
Sorted by: Best Match Show Resources per page
Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program.

Clinical pharmacology and therapeutics

Galluppi GR, Brar S, Caro L, Chen Y, Frey N, Grimm HP, Rudd DJ, Li CC, Magee M, Mukherjee A, Nagao L, Purohit VS, Roy A, Salem AH, Sinha V, Suleiman AA, Taskar KS, Upreti VV, Weber B, Cook J.
PMID: 33991429
Clin Pharmacol Ther. 2021 Nov;110(5):1172-1175. doi: 10.1002/cpt.2265. Epub 2021 May 15.

No abstract available.

Cite
Galluppi GR, Brar S, Caro L, et al. Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program. Clin Pharmacol Ther. 2021;110(5):1172-1175doi: 10.1002/cpt.2265.
Galluppi, G. R., Brar, S., Caro, L., Chen, Y., Frey, N., Grimm, H. P., Rudd, D. J., Li, C. C., Magee, M., Mukherjee, A., Nagao, L., Purohit, V. S., Roy, A., Salem, A. H., Sinha, V., Suleiman, A. A., Taskar, K. S., Upreti, V. V., Weber, B., & Cook, J. (2021). Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program. Clinical pharmacology and therapeutics, 110(5), 1172-1175. https://doi.org/10.1002/cpt.2265
Galluppi, Gerald R, et al. "Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program." Clinical pharmacology and therapeutics vol. 110,5 (2021): 1172-1175. doi: https://doi.org/10.1002/cpt.2265
Galluppi GR, Brar S, Caro L, Chen Y, Frey N, Grimm HP, Rudd DJ, Li CC, Magee M, Mukherjee A, Nagao L, Purohit VS, Roy A, Salem AH, Sinha V, Suleiman AA, Taskar KS, Upreti VV, Weber B, Cook J. Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program. Clin Pharmacol Ther. 2021 Nov;110(5):1172-1175. doi: 10.1002/cpt.2265. Epub 2021 May 15. PMID: 33991429; PMCID: PMC8596613.
Copy Download .nbib Format: NLM
Blockchain Medledger: Hyperledger fabric enabled drug traceability system for counterfeit drugs in pharmaceutical industry.

International journal of pharmaceutics

Uddin M.
PMID: 33549813
Int J Pharm. 2021 Mar 15;597:120235. doi: 10.1016/j.ijpharm.2021.120235. Epub 2021 Feb 04.

Counterfeit drugs are one of the most severe threats to the pharmaceutical industry. World Health Organization (WHO) highlights that nearly 1035% of the drugs, i.e., one out of ten medicines produced in the least developing countries, are counterfeit and...

Cite
Uddin M. Blockchain Medledger: Hyperledger fabric enabled drug traceability system for counterfeit drugs in pharmaceutical industry. Int J Pharm. 2021;597:120235doi: 10.1016/j.ijpharm.2021.120235.
Uddin, M. (2021). Blockchain Medledger: Hyperledger fabric enabled drug traceability system for counterfeit drugs in pharmaceutical industry. International journal of pharmaceutics, 597120235. https://doi.org/10.1016/j.ijpharm.2021.120235
Uddin, Mueen. "Blockchain Medledger: Hyperledger fabric enabled drug traceability system for counterfeit drugs in pharmaceutical industry." International journal of pharmaceutics vol. 597 (2021): 120235. doi: https://doi.org/10.1016/j.ijpharm.2021.120235
Uddin M. Blockchain Medledger: Hyperledger fabric enabled drug traceability system for counterfeit drugs in pharmaceutical industry. Int J Pharm. 2021 Mar 15;597:120235. doi: 10.1016/j.ijpharm.2021.120235. Epub 2021 Feb 04. PMID: 33549813.
Copy Download .nbib Format: NLM
Rewarding innovation in drug discovery.

Health affairs (Project Hope)

Lopes G.
PMID: 19414906
Health Aff (Millwood). 2009 May-Jun;28(3):922-3. doi: 10.1377/hlthaff.28.3.922-a.

No abstract available.

Cite
Lopes G. Rewarding innovation in drug discovery. Health Aff (Millwood). 2009;28(3):922-3doi: 10.1377/hlthaff.28.3.922-a.
Lopes, G. (2009). Rewarding innovation in drug discovery. Health affairs (Project Hope), 28(3), 922-3. https://doi.org/10.1377/hlthaff.28.3.922-a
Lopes, Gilberto. "Rewarding innovation in drug discovery." Health affairs (Project Hope) vol. 28,3 (2009): 922-3. doi: https://doi.org/10.1377/hlthaff.28.3.922-a
Lopes G. Rewarding innovation in drug discovery. Health Aff (Millwood). 2009 May-Jun;28(3):922-3. doi: 10.1377/hlthaff.28.3.922-a. PMID: 19414906.
Copy Download .nbib Format: NLM
COP26 diary: a moment among the business people.

BMJ (Clinical research ed.)

Smith R.
PMID: 34764154
BMJ. 2021 Nov 11;375:n2768. doi: 10.1136/bmj.n2768.

No abstract available.

Cite
Smith R. COP26 diary: a moment among the business people. BMJ. 2021;375:n2768doi: 10.1136/bmj.n2768.
Smith, R. (2021). COP26 diary: a moment among the business people. BMJ (Clinical research ed.), 375n2768. https://doi.org/10.1136/bmj.n2768
Smith, Richard. "COP26 diary: a moment among the business people." BMJ (Clinical research ed.) vol. 375 (2021): n2768. doi: https://doi.org/10.1136/bmj.n2768
Smith R. COP26 diary: a moment among the business people. BMJ. 2021 Nov 11;375:n2768. doi: 10.1136/bmj.n2768. PMID: 34764154.
Copy Download .nbib Format: NLM
The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules.

Molecules (Basel, Switzerland)

Torre BG, Albericio F.
PMID: 33504104
Molecules. 2021 Jan 25;26(3). doi: 10.3390/molecules26030627.

Although the pharmaceutical industry will remember 2020 as the year of COVID-19, it is important to highlight that this year has been the second-best-together with 1996-in terms of the number of drugs accepted by the US Food and Drug...

Cite
Torre BG, Albericio F. The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules. 2021;26(3)doi: 10.3390/molecules26030627.
Torre, B. G., & Albericio, F. (2021). The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules (Basel, Switzerland), 26(3), . https://doi.org/10.3390/molecules26030627
Torre, Beatriz G de la, and Albericio, Fernando. "The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules." Molecules (Basel, Switzerland) vol. 26,3 (2021). doi: https://doi.org/10.3390/molecules26030627
Torre BG, Albericio F. The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules. 2021 Jan 25;26(3). doi: 10.3390/molecules26030627. PMID: 33504104; PMCID: PMC7865374.
Copy Download .nbib Format: NLM
Application of Feature Extraction Methods for Chemical Risk Classification in the Pharmaceutical Industry.

Sensors (Basel, Switzerland)

Topolski M.
PMID: 34502644
Sensors (Basel). 2021 Aug 26;21(17). doi: 10.3390/s21175753.

The features that are used in the classification process are acquired from sensor data on the production site (associated with toxic, physicochemical properties) and also a dataset associated with cybersecurity that may affect the above-mentioned risk. These are large...

Cite
Topolski M. Application of Feature Extraction Methods for Chemical Risk Classification in the Pharmaceutical Industry. Sensors (Basel). 2021;21(17)doi: 10.3390/s21175753.
Topolski, M. (2021). Application of Feature Extraction Methods for Chemical Risk Classification in the Pharmaceutical Industry. Sensors (Basel, Switzerland), 21(17), . https://doi.org/10.3390/s21175753
Topolski, Mariusz. "Application of Feature Extraction Methods for Chemical Risk Classification in the Pharmaceutical Industry." Sensors (Basel, Switzerland) vol. 21,17 (2021). doi: https://doi.org/10.3390/s21175753
Topolski M. Application of Feature Extraction Methods for Chemical Risk Classification in the Pharmaceutical Industry. Sensors (Basel). 2021 Aug 26;21(17). doi: 10.3390/s21175753. PMID: 34502644; PMCID: PMC8434006.
Copy Download .nbib Format: NLM
Paul Brown. Interview by Asher Mullard.

Nature reviews. Drug discovery

Brown P.
PMID: 21959279
Nat Rev Drug Discov. 2011 Sep 30;10(10):726. doi: 10.1038/nrd3575.

No abstract available.

Cite
Brown P. Paul Brown. Interview by Asher Mullard. Nat Rev Drug Discov. 2011;10(10):726doi: 10.1038/nrd3575.
Brown, P. (2011). Paul Brown. Interview by Asher Mullard. Nature reviews. Drug discovery, 10(10), 726. https://doi.org/10.1038/nrd3575
Brown, Paul. "Paul Brown. Interview by Asher Mullard." Nature reviews. Drug discovery vol. 10,10 (2011): 726. doi: https://doi.org/10.1038/nrd3575
Brown P. Paul Brown. Interview by Asher Mullard. Nat Rev Drug Discov. 2011 Sep 30;10(10):726. doi: 10.1038/nrd3575. PMID: 21959279.
Copy Download .nbib Format: NLM
Showing 1537 to 1543 of 1543 entries